NEW YORK (GenomeWeb News) – Agilent subsidiary Dako has entered into a "master framework agreement" with Eli Lilly to advance a companion diagnostic that gauges best responders for an undisclosed oncology treatment the drug maker is developing.

Although the initial focus of the collaboration will be to develop a test to accompany the specific drug, the framework agreement includes opportunities to expand the Rx/Dx partnership for other agents in Lilly's oncology pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.